Bilen Yara, Almoushref Allaa, Alkwatli Kenda, Osman Omar, Mehdi Ali, Sawaf Hanny
Cleveland Clinic, Department of Internal Medicine, Cleveland, OH, United States.
Cleveland Clinic, Department of Kidney Medicine, Cleveland, OH, United States.
Front Med (Lausanne). 2023 Dec 1;10:1264497. doi: 10.3389/fmed.2023.1264497. eCollection 2023.
Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease. In the early 90s, angiotensin blockade (ACEi and ARBs) was introduced, which revolutionized the treatment of DKD. In recent years, newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin antagonists, and mineralocorticoid receptor antagonists (MRA) have shown great promise in reducing albuminuria and protecting the kidneys. These drugs are being used in combination with lifestyle modifications, patient education, and risk factor modification to effectively manage DKD. In this review, we will explore the latest pharmacological options, their efficacy, and their potential to revolutionize the management of this debilitating disease.
糖尿病肾病（DKD）是糖尿病的一种并发症，可导致肾衰竭。多年来，已研发出多种药物来对抗这种疾病。在90年代初，引入了血管紧张素阻断剂（ACEi和ARBs），这彻底改变了DKD的治疗方式。近年来，新型药物如钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂、胰高血糖素样肽-1（GLP-1）受体激动剂、内皮素拮抗剂和盐皮质激素受体拮抗剂（MRA）在减少蛋白尿和保护肾脏方面显示出巨大潜力。这些药物正与生活方式改变、患者教育和危险因素修正相结合，以有效管理DKD。在本综述中，我们将探讨最新的药理学选择、它们的疗效以及它们彻底改变这种使人衰弱疾病管理方式的潜力。
